Skip to main content

Table 2 Disease progression from ASCUS to HSIL by HPV types

From: Enhanced disease progression due to persistent HPV-16/58 infections in Korean women: a systematic review and the Korea HPV cohort study

  N Progression Probability of progression within 36 months (95% CI)a Hazard ratio (95% CI) P valuec
Unadjusted Adjustedb
ASCUS to HSIL 441 60 17.6 (13.3–21.7)    
Age
 20–29 76 7 13.9 (3.4–23.4) Ref Ref  
 30–39 142 21 18.4 (10.8–25.5) 1.64 (0.70–3.87) 1.51 (0.64–3.56) 0.351
 40–49 128 20 19.7 (11.4–27.3) 1.65 (0.70–3.91) 1.67 (0.70–4.00) 0.245
 50–59 95 12 15.9 (6.7–24.1) 1.32 (0.52–3.36) 1.21 (0.47–3.10) 0.699
HPV type at baseline
 Low-risk 155 10 8.6 (3.1–13.8) Ref Ref  
 HPV-16 93 15 19.7 (9.9–28.4) 2.67 (1.12–5.94) 2.64 (1.18–5.90) 0.018
 HPV-18 44 3 10.6 (0.0–21.5) 1.15 (0.32–4.17) 1.08 (0.29–3.97) 0.913
 HPV-31 24 6 30.9 (5.8–49.3) 4.01 (1.46–11.04) 3.96 (1.43–10.94) 0.008
 HPV-33 18 3 20.6 (0.0–39.0) 2.42 (0.67–8.81) 2.34 (0.64–8.54) 0.198
 HPV-45 13 2 20.5 (0.0–42.3) 2.24 (0.49–10.21) 2.16 (0.47–9.90) 0.320
 HPV-52 87 12 19.6 (8.2–29.5) 2.37 (1.02–5.48) 2.32 (1.00–5.42) 0.051
 HPV-58 89 21 28.5 (16.9–38.4) 3.64 (1.71–7.73) 3.54 (1.66–7.55) 0.001
Type-specific persistent infection 200 28 30.7 (14.6–43.7)    
 Low-risk 88 4 6.6 (0.0–12.9) Ref Ref  
 HPV-16 27 6 29.2 (5.2–47.1) 4.86 (1.37–17.23) 5.04 (1.40–18.11) 0.013
 HPV-18 10 2 28.9 (0.0–56.7) 4.13 (0.76–22.65) 4.59 (0.82–25.70) 0.083
 HPV-31 8 2 31.4 (0.0–59.7) 4.12 (0.75–22.56) 3.86 (0.70–21.39) 0.122
 HPV-33 6 1 33.3 (0.0–70.0) 2.58 (0.29–23.46) 3.01 (0.33–27.56) 0.331
 HPV-45 4 1 NA 3.01 (0.34–27.02) 2.80 (0.31–25.27) 0.359
 HPV-52 34 4 13.8 (0.0–27.6) 2.43 (0.61–9.74) 2.57 (0.64–10.39) 0.185
 HPV-58 33 10 61.7 (6.1–84.4) 5.46 (1.71–17.42) 5.84 (1.83–18.67) 0.003
  1. ASCUS: Atypical squamous cells of uncertain significance; LSIL: Low-grade squamous intraepithelial lesion; HSIL: High-grade squamous intraepithelial lesion; 95% CI: 95% confidence interval
  2. aProbabilities of progression were estimated by Kaplan–Meier survival analysis
  3. bHazard ratios and 95% confidence intervals were adjusted by age and genotype
  4. cP values were calculated in the adjusted analysis